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hexose was galactose (40.9) with smaller proportions 
of glucosamine and galactosamine (24.6 and 21.9 
respectively). Fucose (12.6) approached a signifi-
cant decrease in H. contortus infected (6.3) and O. 
circumcincta infected sheep (8.3). galactosamine 
was lower in infected animals than in worm-free 
sheep. There was no difference in the proportion 
of galactose between uninfected and H. contortus 
infected animals (40.2) whereas it increased in those 
O. circumcincta infected (62.9). The study showed 
that parasitism caused changes in the ratio of hexo-
ses and hexosamines in gastrointestinal mucins of 
sheep.
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a common problem with estimating the contamina-
tion of pasture with sheep parasitic larvae is obtain-
ing an accurate estimate of the population from a plot 
sample. Even if the plot correctly representated the 
whole pasture, recovery of worms using standard 
methods can vary from 20 to 80%. Experiments were 
carried out to assess the loss of worms at each step 
through the process of larval recovery from stan-
dardised grass samples. a counted number (100, 500 
or 1000) of fluorescently-labelled Haemonchus con-
tortus larvae (l3) was incubated on grass overnight 
and then recovered by baermannisation for 4–48 h. 
The baermannising solutions included water, bleach 
0.13%, Triton X100 (1% or 0.5%) or Pyroneg 0.4%. 
To identify points within the technique where larvae 
might be lost, larvae remaining in pipettes, beakers 
and different layers of the baermannising solution 
were counted. The highest recovery (50%), while 
maximising consistency, was with 500 larvae and 
baermannisation for 48 h in water. Higher recovery, 
but greater variability (30–90%) was obtained us-
ing the bleach solution. Treatments such as adding 
detergents Triton X100 or Pyroneg had little effect 
(20–45%) on improving recovery. Flushing pipettes 
with water after each handling process of the larvae 
reduced the loss by only 1% and siliconising the 
glassware to avoid adhesion to the glass surface by 
2%. The 40% not recovered are likely to be left on 
grass. Overall the most consistent method for worm 
recovery was baermannising using siliconised glass-
ware, for 48 h at room temperature.
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The presence of abomasal parasites is thought to 
be associated with an increase in the permeability 
of the gastric epithelium. Epithelial permeability is 
regulated by junctional complexes between adjacent 
cells. The most apical component of this junctional 
complex is the tight junction which functions as 
a paracellular diffusion barrier. any disruption of 
tight junctions results in impaired barrier function 
and an associated increase in epithelial permeabil-
ity. To investigate the effect of abomasal parasites 
on the integrity and barrier function of epithelia, 
Caco-2 cell monolayers were exposed to the excre-
tory/secretory products (ES) of adult Ostertagia 
(Teladorsagia) circumcincta and Haemonchus con-
tortus. Changes in epithelial barrier function were 
monitored by measuring transepithelial electrical 
resistance (TEER) and tight junction integrity was 
visualised using immunofluorescence localisation of 
the tight junction-associated proteins, occludin and 
zonula occludens-1 (ZO-1), by confocal microsopy. 
under control conditions, occludin and ZO-1 were 
localised to a continuous pericellular ring around 
individual cells when viewed from the apical sur-
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face. in cells exposed to ES for 24 h, staining of this 
pericellular ring was diminished in intensity and 
corresponded with an increase in the presence of 
punctuate, intracellular staining. Exposure to ES was 
also shown to interfere with tight junction integrity, 
which was detected as a decrease in TEER from 678 
± 10 Ωcm2 (control) to 526 ± 8 Ωcm2 (ES-treated) 
(n = 12) in 6 h. These alterations in TEER, along 
with intracellular changes in occludin and ZO-1 
distribution, suggest that parasite ES disrupts tight 
junctions, leading to an increase in epithelial perme-
ability which may be of importance in the pathology 
of abomasal parasitism.
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macrolide antiparasitic agents including abamectin, 
are used extensively in New Zealand. although 
the sensitivity of collie and collie-crosses with the 
mDR1 gene mutation to macrolide parasiticides is 
well documented, abamectin toxicity in other breeds 
of dogs without this mutation is not well known. 
Cases of serious toxicity and deaths in farm dogs 
exposed to abamectin pour-on products highlight 
the risks of exposure in working dogs.
 Clinical signs of toxicity include dilated pupils, 
blindness, tremors, ataxia, vomiting, hypersalivation, 
depression, coma and death. There is no antidote for 
macrolide antiparasiticides, but symptomatic treat-
ment will result in a favourable outcome in many 
dogs. The prognosis depends on the amount of com-
pound ingested and the severity of the clinical signs. 
if the dog becomes comatose, recovery may take 
several weeks. Blindness is usually reversible.
 a farmer treated his cattle with an abamectin 
pour-on. The following day one farm dog was found 
dead in its kennel and four other dogs showed a 
range of signs from ataxia to depression. a blood 
sample from one of the more severely affected dogs 
had a plasma abamectin concentration of 0.149 mg/
litre. in comparison, beagles given a topical exposure 
of 6 mg/kg had a peak plasma level of 0.022 mg/
litre. The lD50 of orally dosed abamectin in dogs 
is reported as approximately 8 mg/kg. Farmers us-
ing pour-on products, which contain 10 mg/ml of 
abamectin, need to be aware of the danger to their 
working dogs.
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a vaccine to prevent sheep getting hydatid disease 
was invented at Wallaceville animal Research Cen-
tre. it was patented in 1993 in New Zealand, austra-
lia, mongolia, Bulgaria, Hungary, Brazil, ukraine, 
Europe, Japan, uSa, Chile, uruguay and Russia. 
yearly renewals are very costly so most protection 
was relinquished by 2000. marketing problems in-
cluded the following: 
(1) interest was expressed mainly from Third-World 
Countries where patents were not recognised, 
including argentina, Peru, Bolivia, Paraguay, all 
the Eastern Russian “Stan” countries, China, all 
of the middle East, and all of africa.
(2) Before 1990, the necessary molecular biology 
skills were not available in New Zealand, so 
cloning of the New Zealand-identified protective 
molecule was done by melbourne university. 
For this service they have always insisted on 
50% of any royalties that may be generated.
(3) The Eg95 vaccine was transformed into E. coli 
and expressed as inclusion bodies, which fa-
cilitated purification of large amounts of pro-
tein. after production technology capable of 
scaling-up to 1000 litre level was developed in 
New Zealand, we began technology transfer to 
an Argentine firm (1997). This move coincided 
with the crash of the argentinian economy, and 
the project was dropped. another argentinian 
firm is now (2008) starting to make the vac-
cine.
(4) China was interested in the vaccine, and 3 years 
of field trials using the New Zealand vaccine 
were successful (1999). a factory was built in 
Beijing and scientists trained at Wallaceville 
(2001) and we supervised the production of an 
excellent batch of vaccine (2003). Extensive 
safety trials were then required and were com-
pleted in 2005. The registration document was 
then assembled and registration was granted in 
June 2007. The factory then had to be moved 
from a centre of habitation, so it is being built 
again. Chinese authorities concerned with hy-
datid control are now calling for the vaccine, 
but it is still not available.
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